Next Article in Journal
The Application of Adeno-Associated Viral Vector Gene Therapy to the Treatment of Fragile X Syndrome
Next Article in Special Issue
Assessing Anxiety Disorders Using Wearable Devices: Challenges and Future Directions
Previous Article in Journal
Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
Previous Article in Special Issue
Alterations in Motor Cortical Representation of Muscles Following Incomplete Spinal Cord Injury in Humans
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessCase Report

Missed Diagnosis of Major Depressive Disorder with Catatonia Features

1
School of Medicine, Avalon University, Girard, OH 44420, USA
2
Department of Psychiatry, Griffin Memorial Hospital, Norman, OK 73071, USA
*
Author to whom correspondence should be addressed.
Brain Sci. 2019, 9(2), 31; https://doi.org/10.3390/brainsci9020031
Received: 21 December 2018 / Revised: 29 January 2019 / Accepted: 30 January 2019 / Published: 2 February 2019
(This article belongs to the Collection Collection on Clinical Neuroscience)
  |  
PDF [165 KB, uploaded 2 February 2019]
  |  

Abstract

Catatonia is often a presentation of extreme anxiety and depression. Missing the diagnosis of catatonia would lead to improper treatment, which could be life-threatening. A thorough physical and psychiatric assessment is required for detecting the catatonic symptoms, especially, mutism and negativism in patients with depression. We discuss the case of a 58-year-old female that was incorrectly diagnosed and treated for major depressive disorder (MDD). The patient was then correctly diagnosed with MDD with catatonic features and improved once benzodiazepine (BZD) was started. The preferred BZD was lorazepam, with a success rate of complete remission of up to 80% in adults. Treatment was started with lorazepam 1–2 mg and improvement was seen within the first ten minutes. We believed the addition of BZD in a psychotropic regimen could improve both catatonia and depression, and should be continued for 3–6 months to prevent relapses and recurrences. View Full-Text
Keywords: catatonia; MDD; depression; BZD; benzodiazepine; anxiety; lorazepam; clinical improvement catatonia; MDD; depression; BZD; benzodiazepine; anxiety; lorazepam; clinical improvement
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Jhawer, H.; Sidhu, M.; Patel, R.S. Missed Diagnosis of Major Depressive Disorder with Catatonia Features. Brain Sci. 2019, 9, 31.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top